溢多利(300381) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue decreased by 1.18% compared to the previous year[5]. - The net profit attributable to shareholders decreased by 173.53% year-on-year, primarily due to asset impairment losses, rising raw material and energy prices, and production limitations caused by power outages[5]. - The company's operating revenue for 2021 was ¥1,892,160,336.27, a decrease of 1.18% compared to ¥1,914,764,458.88 in 2020[19]. - The net profit attributable to shareholders was -¥118,910,123.08 in 2021, representing a decline of 173.53% from ¥161,706,004.11 in 2020[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥133,979,417.42, a decrease of 219.72% compared to ¥111,906,716.13 in 2020[19]. - The net cash flow from operating activities was ¥216,929,263.66, down 46.27% from ¥403,726,106.50 in 2020[19]. - The total assets at the end of 2021 were ¥4,479,934,615.27, a decrease of 4.12% from ¥4,672,225,564.65 at the end of 2020[19]. - The net assets attributable to shareholders decreased by 6.22% to ¥2,792,803,878.46 at the end of 2021 from ¥2,978,092,925.07 at the end of 2020[19]. - The basic earnings per share for 2021 was -¥0.2426, a decline of 169.89% from ¥0.3471 in 2020[19]. - The company reported a significant drop in quarterly net profit in Q4 2021, with a loss of -¥190,084,694.34 compared to profits in the first three quarters[22]. Strategic Initiatives - The company plans to sell assets related to its biopharmaceutical segment to alleviate operational burdens and enhance cash flow, which may lead to short-term performance fluctuations[5]. - The company is increasing its investment in the industrial enzyme sector, which is considered a blue ocean market, to maintain competitive advantages amid intensifying market competition[5]. - The company aims to become a leading enterprise in functional feed additives in China, leveraging nearly 30 years of accumulated customer channel advantages[34]. - The company is the largest supplier of feed enzymes in China and plans to expand its international presence to capture additional market share[34]. - The company is currently planning to divest its pharmaceutical business assets while continuing its operations in the biopharmaceutical and biomanufacturing sectors[35]. - The company plans to enhance its product offerings and expand market reach through ongoing research and development initiatives[45]. Market Trends and Demand - The company operates in the growing bioenzyme and steroid hormone raw material sectors, with increasing demand expected in downstream industries[29]. - The functional feed additive market in China grew from RMB 25.05 billion in 2009 to RMB 48.4 billion in 2017, with a CAGR of approximately 9%[31]. - The demand for functional feed additives is expected to increase due to the "antibiotic-free" trend, leading to accelerated industry consolidation and growth opportunities for companies with core technologies[31]. - The market for functional feed additives is expected to expand significantly following the implementation of the Ministry of Agriculture's 2019 announcement banning growth-promoting drug additives in feed[34]. Research and Development - The company has a strong focus on research and development, holding 227 invention patents and 5 new veterinary drug product certificates[42]. - Research and development expenses increased by 5.66%, attributed to new technology introductions and increased personnel costs[45]. - The number of R&D personnel grew by 9.65% to 409, with a higher proportion of staff holding bachelor's and master's degrees[66]. - The company is actively involved in research and development of new products and technologies in the biopharmaceutical sector[82]. Environmental Compliance - The company reported a total of 749.32 tons of hazardous waste collected and treated, with no exceedances of the approved discharge limits[171]. - The company’s total nitrogen discharge was 1.008 tons, which is below the regulatory limit of 40 mg/l[171]. - The company’s total phosphorus discharge was 0.144 tons, which is below the regulatory limit of 4 mg/l[171]. - The company has a wastewater treatment capacity of 4,000 tons per day, ensuring compliance with environmental standards[176]. - The company has established emergency response plans for environmental incidents, which have been filed with local environmental protection bureaus, and conducts regular training and drills to enhance response capabilities[181]. Governance and Management - The company has established a governance structure that complies with the requirements of the Company Law and the Shenzhen Stock Exchange regulations, ensuring effective management and risk control[113]. - The board of directors consists of 7 members, including 3 independent directors, and has established four specialized committees to enhance decision-making and oversight[114]. - The company maintains independence from its controlling shareholder in terms of business operations, personnel, assets, and financial management, ensuring no interference in its operations[117]. - The company has implemented a performance evaluation and incentive mechanism that aligns employee compensation with performance, promoting accountability among senior management[114]. - The company has a complete and independent financial management system, with dedicated accounting personnel and independent decision-making capabilities[117]. Shareholder Engagement - The company reported a cash dividend of 1.00 yuan per 10 shares, totaling 49,006,731.60 yuan, which accounted for 100% of the total profit distribution[151]. - The proposed profit distribution plan for 2021 includes a cash dividend of 1.00 RMB per 10 shares, totaling 49,006,731.60 RMB, which will not include stock dividends or capital reserve transfers[153]. - The company emphasizes shareholder rights protection by ensuring timely and accurate information disclosure in compliance with relevant laws and regulations[188]. - The company has a stable profit distribution policy and dividend plan to reward shareholders[188]. Employee Development - The company focuses on employee rights protection, providing various training programs to enhance employee skills and knowledge[189]. - The company conducted various online training courses during the reporting period to enhance employees' professional knowledge and skills[149]. - The total number of employees at the end of the reporting period was 2,807, including 435 at the parent company and 2,372 at major subsidiaries[146].